ABIGO Medical AB, a Swedish pharmaceutical company specializing in advanced wound care and ear, nose, and throat (ENT) medicine, has been sold to Essity, a listed hygiene specialist known for brands such as Tempo, Tork, and Zewa.
ABIGO Medical AB, founded in 1989 by brothers Jan G. Smith and Leif Smith, who remain actively involved, is a Swedish pharmaceutical company that owns, develops, produces, and markets pharmaceuticals and medical devices. The company's main areas of focus are advanced wound care and ENT medicine.
ABIGO's business philosophy includes an active research and development program in selected areas, leading to international patents and patent applications. The company has developed unique, patented products with international potential in niche areas. ABIGO's commitment to addressing antibiotic resistance—a global problem exacerbated by multi-drug resistant bacteria—is paramount in their R&D efforts. They develop unique solutions utilizing natural processes and physical interactions without chemical agents or surgical intervention.
ABIGO operates internationally, selling products in about 60 countries through its own sales organizations and partners. Its Danish subsidiary, ABIGO Pharma A/S, markets ABIGO products and a wide range of self-care products. The Norwegian subsidiary, ABIGO Medical AS, markets ABIGO's products in Norway. ABIGO Medical AB also includes the subsidiary Sylak AB.
Essity, headquartered in Stockholm, is a listed manufacturer of tissue paper that originated from SCA and is a global market leader in this field. In the medical products sector, Essity is represented by BSN medical and Tena (urinary incontinence). Essity employs around 47,000 people worldwide and generated sales of approximately 12 billion euros in 2018.
Essity's best-known brands in German-speaking countries include Tempo, Tork, and Zewa. The company previously owned the "Softis" handkerchief brand, which was sold to Sofidel in 2007 for antitrust reasons following the acquisition of "Tempo." However, Essity retains a license to distribute "Softis" outside Germany and Austria.
ConAlliance is one of the leading M&A advisory firms specializing in comprehensive support for company sales and acquisitions within the healthcare sector. Since its founding in 2011, ConAlliance has successfully supported over 100 mandates.
ConAlliance's expertise is entirely focused on corporate transactions in the healthcare sector. Core competencies include medical technology, medical devices, pharmaceuticals, nursing and hospital care, healthcare IT, and other manufacturing and service companies in the global healthcare industry, as well as healthcare real estate.
For more information about ConAlliance, please visit www.conalliance.com.